← The record

Glycomacropeptide Formula With Long Chain Polyunsaturated Fatty Acids And Docosahexaenoic Acid And Low In Phenylalanine

Recommended MetabolicRestrictedNot applicable line

Dietary management of phenylketonuria (PKU) in children from 3 years of age and adults.

2
Submissions
2022–26
On the record
—
ICER range
Cost-min
Cost basis

Decision on record

1 decision
  • Meeting Nov 2022 Recommended Phenylketonuria

Access path

2 submissions · public record
  1. Nov 2022
    Recommended · restricted

    vs PKU Sphere20 Powder

  2. Mar 2026
    Recommended · restricted

    Comparator changed: PKU Sphere20 Powder → PKU Sphere20 (glycomacropeptide formula with…

  3. PBS listing · Restricted
RecommendedDeferredNot recommended

From the public summary

Verbatim · PSD text · may span indications
PBAC outcome
7.1 The PBAC recommended a General Schedule Restricted Benefit listing of glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine (PKU GMPro Delight®) sachets containing oral powder 40 g for the dietary management of phenylketonuria (PKU) under the same circumstances as glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in phenylalanine (PKU …PSD · Mar 2026
7.2 The PBAC considered that PKU GMPro Delight should be cost-minimised to PKU Sphere20, the comparator accepted by the NPWP at an equivalent price per gram of PE.PSD · Mar 2026
Economic analysis
5.12 The submission presented a cost-minimisation approach of PKU Sphere Liquid compared with PKU Sphere20 Powder, based on the same price per gram PE of $0.76 at the approved ex-manufacturer price (AEMP).PSD · Nov 2022
5.13 The proposed AEMP per maximum quantity PE ($1,827.68) is the same as the main comparator PKU Sphere20 Powder. The PBAC considered this to be appropriate as PKU Sphere Liquid contains the same PE as PKU Sphere20 Powder.PSD · Nov 2022
Clinical claim
5.5 The submission claimed the nutritional composition of PKU GMPro Delight is therapeutically equivalent to PKU Sphere20 and is expected to deliver comparable clinical outcomes. The submission provided a comparison of the nutritional profile of PKU GMPro Delight with PKU Sphere20 (Table 2).PSD · Mar 2026
5.6 The submission stated one 160 ml serving (40 g powder in 140 ml water) PKU GMPro Delight provides 519 kJ/ 122 kcal, 20 g protein equivalent (PE); 36 mg phenylalanine (PHE), and 100 mg docosahexaenoic acid (DHA).PSD · Mar 2026
Consumer comments
5.8 The submission stated PKU Sphere Liquid is less concentrated in PE than PKU Sphere20 Powder. The submission considered patients who switch to PKU Sphere Liquid will require more formulation volume per day of PKU Sphere Liquid to maintain the same level of metabolic control as PKU Sphere20 Powder. The submission considered the extra volume of formulation will not introduce additional calories.PSD · Nov 2022
5.9 The submission stated PKU Sphere Liquid has higher concentration of PE than PKU GMPro LQ and considered patients will require less formulation volume of PKU Sphere Liquid per day to maintain the same level of metabolic control as PKU GMPro LQ. The submission argued PKU Sphere Liquid may improve dietary compliance for patients struggling to consume the large volume. The submission also stated PKU Sphere Liquid contains fewer calories than PKU GMPro LQ.PSD · Nov 2022

Cost-effectiveness

Cost-minimisation submission; no ICER calculated. PBAC recommended cost-minimisation to PKU Sphere20 at equivalent price per gram of protein equivalent, but the requested AEMP for PKU GMPro Delight ($0.825 per gram PE) was higher than PKU Sphere20 ($0.76 per gram PE).

The PBAC considered that PKU GMPro Delight should be cost-minimised to PKU Sphere20, the comparator accepted by the NPWP at an equivalent price per gram of PE. PBAC · 2026
Cost-effectiveness accepted

Decision context

PopulationChildren from 3 years of age and adults with phenylketonuria (PKU) requiring dietary management.

Submission history

2 entries
DecidedOutcomeComparatorICEREvidence
Mar 2026 Recommended · restricted PKU Sphere20 (glycomacropeptide formula with long chain polyunsaturated fatty acids and docosahexaenoic acid and low in — Cost-minimisation
Nov 2022 Recommended · restricted PKU Sphere20 Powder — Cost-minimisation · Cost-minimisation

Similar precedents

By decision profile

Regulatory · TGA

Label narrower than PBS population — PBAC restricts to PKU patients requiring glycomacropeptide-based formula; TGA label covers all food for special medical purposes.

Listed in law

Federal Register of Legislation

PBS listings commencing 1 May 2023 were made by these 5 determinations under the National Health Act 1953. A determination covers every listing that commenced that day, so this is the legal instrument in force for the date — not a document naming this medicine. Open it and check.

DeterminationMadeStatus
PB 34 of 2023 27 Apr 2023 Repealed PDF ↗
PB 35 of 2023 27 Apr 2023 Repealed PDF ↗
PB 35 of 2023 27 Apr 2023 Repealed PDF ↗
PB 36 of 2023 27 Apr 2023 Repealed PDF ↗
PB 41 of 2023 1 May 2023 Repealed PDF ↗